About Black Diamond Therapeutics, Inc.
https://www.blackdiamondtherapeutics.comBlack Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations.
CEO
Mark A. Velleca
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 35
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:10.74M
Value:$29.98M
VESTAL POINT CAPITAL, LP
Shares:5.55M
Value:$15.48M
NEA MANAGEMENT COMPANY, LLC
Shares:4.45M
Value:$12.41M
Summary
Showing Top 3 of 105
About Black Diamond Therapeutics, Inc.
https://www.blackdiamondtherapeutics.comBlack Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $10.98M ▼ | $-8.5M ▲ | 0% | $-0.15 ▲ | $-8.41M ▲ |
| Q2-2025 | $0 ▼ | $13.33M ▼ | $-10.56M ▼ | 0% ▼ | $-0.19 ▼ | $-10.47M ▼ |
| Q1-2025 | $70M ▲ | $15.47M ▼ | $56.54M ▲ | 80.77% ▲ | $1 ▲ | $54.62M ▲ |
| Q4-2024 | $0 | $18.27M ▲ | $-15.98M ▼ | 0% | $-0.28 | $-18.19M ▼ |
| Q3-2024 | $0 | $18.13M | $-15.56M | 0% | $-0.28 | $-18.04M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $135.5M ▼ | $157.73M ▼ | $31.58M ▼ | $126.15M ▼ |
| Q2-2025 | $142.83M ▼ | $166.38M ▼ | $33.77M ▼ | $132.61M ▼ |
| Q1-2025 | $152.4M ▲ | $176.25M ▲ | $34.73M ▼ | $141.52M ▲ |
| Q4-2024 | $98.58M ▼ | $122.64M ▼ | $39.35M ▼ | $83.28M ▼ |
| Q3-2024 | $112.68M | $137.9M | $40.47M | $97.43M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-8.5M ▲ | $-7.85M ▲ | $8.59M ▲ | $134K ▲ | $874K ▲ | $-7.85M ▲ |
| Q2-2025 | $-10.56M ▼ | $-9.16M ▼ | $-59.15M ▼ | $-116K ▼ | $-68.43M ▼ | $-9.16M ▼ |
| Q1-2025 | $56.54M ▲ | $53.41M ▲ | $8.55M ▼ | $32K ▼ | $61.99M ▲ | $53.41M ▲ |
| Q4-2024 | $-15.98M ▼ | $-15.05M ▼ | $27.77M ▲ | $291K ▲ | $13.01M ▲ | $-15.05M ▼ |
| Q3-2024 | $-15.56M | $-11.32M | $2.19M | $-252K | $-9.38M | $-11.32M |
CEO
Mark A. Velleca
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 35
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:10.74M
Value:$29.98M
VESTAL POINT CAPITAL, LP
Shares:5.55M
Value:$15.48M
NEA MANAGEMENT COMPANY, LLC
Shares:4.45M
Value:$12.41M
Summary
Showing Top 3 of 105